Cannabis use and age at onset of psychosis: Further evidence of interaction with COMT Val158Met polymorphism

Acta Psychiatrica Scandinavica

Volumn 123, Issue 6, 2011, Pages 485-492

  Estrada, G ^a   Fatjo Vilas M ^a   Munoz M J ^b   Pulido, G ^b   Minano M J ^c   Toledo, E ^b   Illa, J M ^b   Martin M ^b   Miralles, M L ^b   Miret, S ^d   Campanera, S ^d   Bernabeu, C ^b   Navarro, M E ^b   Fananas L ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Adolescents Unit   (Spain)

^c Parc Taulí Health Corporation   (Spain)

^d Hospital Santa Maria   (Spain)

Author keywords

Age of onset; Cannabis use; COMT; Psychosis; Val158Met polymorphism

Indexed keywords

CANNABIS; CATECHOL METHYLTRANSFERASE; GENOMIC DNA; VALINE;

ADOLESCENT; ADULT; ARTICLE; CANNABIS ADDICTION; CONDUCT DISORDER; CONTROLLED STUDY; DIAGNOSIS RELATED GROUP; DISEASE ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; ONSET AGE; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIA SPECTRUM DISORDER; SCHIZOPHRENIFORM DISORDER; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; AGE OF ONSET; CATECHOL O-METHYLTRANSFERASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; METHIONINE; POLYMORPHISM, GENETIC; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; VALINE;

EID: 79955980417     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2010.01665.x     Document Type: Article

References (67)

1. UNODOC. World drug report. United Nation office on Drugs and Crime. 2008.
2. ESTUDES. Observatorio Español sobre Drogas. Encuesta Estatal sobre las Drogas en Enseñanzas Secundarias, 2006. Madrid: Delegación del Gobierno para el Plan Nacional sobre Drogas, 2008.
3. Armstrong TD, Costello EJ. Community studies on adolescent substance use, abuse, or dependence and psychiatric comorbidity. J Consult Clin Psychol 2002;70:1224-1239.
4. Mazzoncini R, Donoghue K, Hart J et al. Illicit substance use and its correlates in first episode psychosis. Acta Psychiatr Scand 2010;121:351-358.
5. Grech A, Van OS J, Jones PB, Lewis SW, Murray RM. Cannabis use and outcome of recent onset psychosis. Eur Psychiatry 2005;20:349-353.
6. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987;2:1483-1486.
7. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002;325:1199.
8. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002;325:1212-1213.
9. Van OS J, Bak M, Hanssen M, Bijl RV, De Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002;156:319-327.
10. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med 2003;33:15-21.
11. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van OS J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004;99:1333-1341.
12. Moore TH, Zammit S, Lingford-Hughes A et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-328.
13. Henquet C, Krabbendam L, Spauwen J et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005;330:11.
14. Semple DM, Mcintosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005;19:187-194.
15. Konings M, Henquet C, Maharajh HD, Hutchinson G, Van OS J. Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad. Acta Psychiatr Scand 2008;118:209-213.
16. Dragt S, Nieman DH, Becker HE et al. Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. Can J Psychiatry 2010;55:165-171.
17. Veen ND, Selten JP, Van Der Tweel I, Feller WG, Hoek HW, Kahn RS. Cannabis use and age at onset of schizophrenia. Am J Psychiatry 2004;161:501-506.
18. Barnes TR, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 2006;188:237-242.
19. Gonzalez-Pinto A, Vega P, Ibanez B et al. Impact of cannabis and other drugs on age at onset of psychosis. J Clin Psychiatry 2008;69:1210-1216.
20. Pelayo-Teran JM, Perez-Iglesias R, Mata I, Carrasco-Marin E, Vazquez-Barquero JL, Crespo-Facorro B. Catechol-O-Methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affective psychosis: clinical-onset implications. Psychiatry Res 2010;179:291-296.
21. Chevaleyre V, Takahashi KA, Castillo PE. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 2006;29:37-76.
22. Breivogel CS, Sim-Selley LJ. Basic neuroanatomy and neuropharmacology of cannabinoids. Int Rev Psychiatry 2009;21:113-121.
23. De Fonseca FR, Schneider M. The endogenous cannabinoid system and drug addiction: 20years after the discovery of the CB1 receptor. Addict Biol 2008;13:143-146.
24. Gardner EL. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 2005;81:263-284.
25. Fadda P, Scherma M, Spano MS et al. Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport 2006;17:1629-1632.
26. Bossong MG, Van Berckel BN, Boellaard R et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009;34:759-766.
27. Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci 2004;24:4393-4400.
28. Chen J, Paredes W, Lowinson JH, Gardner EL. Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur J Pharmacol 1990;190:259-262.
29. Verrico CD, Jentsch JD, Roth RH. Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. Synapse 2003;49:61-66.
30. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997;276:2048-2050.
31. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull 2009;35:549-562.
32. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 2007;8:885-895.
33. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM. Gene-Environment Interplay Between Cannabis and Psychosis. Schizophr Bull 2008;34:1111-1121.
34. Di Forti M, Morgan C, Dazzan P et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009;195:488-491.
35. Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen JD. Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol Med 2003;33:23-32.
36. Agrawal A, Lynskey MT. Candidate genes for cannabis use disorders: findings, challenges and directions. Addiction 2009;104:518-532.
37. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243-250.
38. Chen J, Lipska BK, Halim N et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004;75:807-821.
39. Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 2006;7:818-827.
40. Goldberg TE, Egan MF, Gscheidle T et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 2003;60:889-896.
41. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003;160:13-23.
42. Fan JB, Zhang CS, Gu NF et al. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. Biol Psychiatry 2005;57:139-144.
43. Munafo MR, Bowes L, Clark TG, Flint J. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies. Mol Psychiatry 2005;10:765-770.
44. Okochi T, Ikeda M, Kishi T et al. Meta-analysis of association between genetic variants in COMT and schizophrenia: an update. Schizophr Res 2009;110:140-148.
45. Caspi A, Moffitt TE, Cannon M et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005;57:1117-1127.
46. Henquet C, Rosa A, Krabbendam L et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006;31:2748-2757.
47. Henquet C, Rosa A, Delespaul P et al. COMT ValMet moderation of cannabis-induced psychosis: a momentary assessment study of 'switching on' hallucinations in the flow of daily life. Acta Psychiatr Scand 2009;119:156-160.
48. Zammit S, Spurlock G, Williams H et al. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry 2007;191:402-407.
49. Kantrowitz JT, Nolan KA, Sen S et al. Adolescent Cannabis Use, Psychosis and Catechol-O-Methyltransferase Genotype in African Americans and Caucasians. Psychiatr Q 2009;80:213-218.
50. APA. American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition). 1st edn. Washington, DC: American Psychiatric Press, 1994.
51. Sham PC, Jones P, Russell A et al. Age at onset, sex, and familial psychiatric morbidity in schizophrenia. Camberwell Collaborative Psychosis Study. Br J Psychiatry 1994;165:466-473.
52. Nurnberger JI Jr, Blehar MC, Kaufmann CA et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994;51:849-859. discussion 63-4.
53. Dean AG, Dean JA, Burton AH, Dicker RC. Epi Info: a general-purpose microcomputer program for public health information systems. Am J Prev Med 1991;7:178-182.
54. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004;184:110-117.
55. Chambers RA, Taylor JR, Potenza MN. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry 2003;160:1041-1052.
56. Sundram S. Cannabis and neurodevelopment: implications for psychiatric disorders. Hum Psychopharmacol 2006;21:245-254.
57. Kendler KS, Schmitt E, Aggen SH, Prescott CA. Genetic and environmental influences on alcohol, caffeine, cannabis, and nicotine use from early adolescence to middle adulthood. Arch Gen Psychiatry 2008;65:674-682.
58. Petraitis J, Flay BR, Miller TQ, Torpy EJ, Greiner B. Illicit substance use among adolescents: a matrix of prospective predictors. Subst Use Misuse 1998;33:2561-2604.
59. Vandenbergh DJ, Rodriguez LA, Miller IT, Uhl GR, Lachman HM. High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet 1997;74:439-442.
60. Ferdinand RF, Sondeijker F, Van Der Ende J, Selten JP, Huizink A, Verhulst FC. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 2005;100:612-618.
61. Weinberger DR, Egan MF, Bertolino A et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001;50:825-844.
62. Pelayo-Teran JM, Crespo-Facorro B, Carrasco-Marin E et al. Catechol-O-methyltransferase Val158Met polymorphism and clinical characteristics in first episode non-affective psychosis. Am J Med Genet B Neuropsychiatr Genet 2008;147B:550-556.
63. Karayiorgou M, Gogos JA, Galke BL et al. Identification of sequence variants and analysis of the role of the catechol-O-methyl-transferase gene in schizophrenia susceptibility. Biol Psychiatry 1998;43:425-431.
64. Tsuang MT, Lyons MJ, Eisen SA et al. Genetic influences on DSM-III-R drug abuse and dependence: a study of 3, 372 twin pairs. Am J Med Genet 1996;20:67. 473-7.
65. Van OSJ, Marcelis M. The ecogenetics of schizophrenia: a review. Schizophr Res 1998;32:127-135.
66. Kendler KS, Karkowski LM, Neale MC, Prescott CA. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry 2000;57:261-269.
67. Gogtay N, Giedd JN, Lusk L et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci USA 2004;101:8174-8179.